KR102496751B1 - Fruits of Acanthopanax sessiliflorus extract including obesity prevention functional ingredients and method for manufacturing it - Google Patents

Abstract

The present invention relates to a method for extracting an extract containing a functional ingredient for preventing obesity from a fruit of Ogapi. Since the extract of the fruit extract of the present invention has an excellent inhibitory effect on weight gain and body fat increase due to obesity, it can be usefully used as a composition for preventing or treating obesity.

Description

Fruits of Acanthopanax sessiliflorus extract including obesity prevention functional ingredients and method for manufacturing it}

The present invention relates to a method for extracting an extract containing a functional ingredient for preventing obesity from a fruit of Ogapi.

In general, obesity generally means a state in which adipose tissue is excessive in the body, and is a phenomenon in which energy consumed from food is not balanced with energy consumed through physical activity and the like, and thus surplus energy is accumulated as body fat. When body fat is abnormally increased due to energy imbalance over a long period of time, various metabolic diseases and adult diseases such as diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, and fatty liver are induced, which is emerging as a serious social problem not only in the West but also in Korea. .

Various aspects of research for the development of anti-obesity drugs are being conducted worldwide. Obesity treatment drugs can be largely divided into inhibition of fat absorption, promotion of lipolysis and heat generation, control of appetite and satiety, inhibition of protein metabolism, and emotional control mechanisms related to food intake. Representative obesity treatments include Xenical™, which uses oristat as a raw material to suppress fat absorption, and Reductil™, which uses sibutramine as a main ingredient to suppress appetite by stimulating the sympathetic nervous system. . However, in the case of Xenical™, side effects such as steatorrhea, abdominal pain, vomiting, itching, and liver damage have been reported, and in the case of Reductil™, side effects such as headache, anorexia, insomnia, and constipation, as well as serious cardiovascular side effects have been reported. Controversy has arisen over the recent strengthening of standards for use.

In addition to drug therapy through these anti-obesity drugs, as a way to prevent and treat obesity, there are diet therapy to limit food intake, exercise therapy to increase energy consumption, and psychotherapy, behavioral therapy, and surgical therapy.

As a preferable method of treating obesity, it is proposed as the safest and most effective method to promote energy consumption through exercise and to use a drug for treating obesity with few side effects. However, in the case of drugs for the treatment of obesity, serious side effects have been reported, as in the examples of Xenical™ and Reductil™, and clear trust in safety is not supported. Therefore, there is a demand for the development of substances that ensure safety while exhibiting excellent anti-obesity efficacy for the human body.

Accordingly, the inventors of the present invention have made efforts to develop natural materials effective for the treatment of obesity without side effects, and have found that the extract of the fruit extract of the present invention has an effect of preventing or treating obesity, and has completed a composition for preventing or treating obesity using the same. .

Korean Registered Patent No. 0996577 Korean Registered Patent No. 0588469

An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity, containing an extract of quinoa as an active ingredient.

In addition, another object of the present invention is to provide a health functional food composition for preventing or improving obesity, including an extract of a cucumber plant.

Another object of the present invention is the step of extracting at 10 to 60 ° C. for 30 minutes to 48 hours by adding 50% ethanol to the pulverized cucumber fruit; And to provide a method for producing a composition for preventing or improving obesity, comprising the step of filtering and concentrating the extracted extract after the extraction and freeze-drying it.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity containing the extract as an active ingredient.

In one embodiment of the present invention, the cucumber extract can extract fruit parts.

In one embodiment of the present invention, the solvent used for the extraction is extracted with any one solvent selected from the group consisting of methanol, ethanol, acetone, ethyl acetate, hexane, butanol, methylene chloride, water or a mixed solvent thereof can

In one embodiment of the present invention, the cucumber extract can be extracted with 50 to 80% ethanol extract at a temperature of 10 to 60 ° C.

In addition, the present invention provides a health functional food composition for preventing or improving obesity, including an extract of quinoa.

In one embodiment of the present invention, the cucumber extract can extract fruit parts.

Furthermore, the present invention includes the steps of extracting at 10 to 60 ° C. for 30 minutes to 48 hours by adding 50% ethanol to the pulverized cucumber fruit; And it provides a method for producing a composition for preventing or improving obesity, comprising the step of filtering and concentrating the extracted extract after the extraction and freeze-drying it.

Since the extract of the fruit extract of the present invention has an excellent inhibitory effect on weight gain and body fat increase due to obesity, it can be usefully used as a composition for preventing or treating obesity.

Figure 1 is a result of confirming the change in body weight by administration of the extract of the fruit extract of the present invention in an animal model for inducing obesity.
2 is a result of confirming the weight of abdominal fat and epididymal fat by administration of the extract of the fruit extract of the present invention in an animal model for inducing obesity.
Figure 3 is a result of confirming the weight of the liver, spleen, lung and kidney in order to confirm the change in organ weight reduction by administration of the extract of the fruit extract of cucumber.

Hereinafter, preferred implementations of the present invention will be described in detail. However, it should be understood that this invention may be embodied in many different forms and is not limited to the described embodiments. It should be noted that the embodiments of the present invention described below are intended to sufficiently convey the spirit of the present invention to those skilled in the art.

In addition, the terms (terminology) used in this specification are terms used to appropriately express preferred embodiments of the present invention, which may vary according to the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the contents throughout this specification. Throughout the specification, when a certain component is said to "include", it means that it may further include other components without excluding other components unless otherwise stated.

The present invention provides a pharmaceutical composition for the prevention or treatment of obesity, comprising an extract of Ogapi as an active ingredient.

In the present invention, the extract may be extracted using any one part selected from the stem, fruit, or root of the cucumber, but among the above-mentioned parts, the extract extracted from the fruit of the cucumber may have a better obesity improvement effect. can

The term "extract" used in the present invention refers to a preparation obtained by extracting cucumbers with an appropriate extraction solvent and evaporating the solvent to concentrate, but is not limited thereto, an extract obtained by extraction treatment, a dilution of the extract, or It may be a dried product obtained by drying a concentrate or an extract, or a crude or purified product thereof. The Ogapi extract can be prepared using a general extraction method, separation and purification method known in the art. The extraction method is not limited thereto, but preferably, methods such as hot water extraction, hot water extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction may be used.

The extract according to the present invention may be obtained by extraction and separation from nature using an extraction and separation method known in the art, and the "extract" defined in the present invention is extracted from cucumber skin using an appropriate solvent, For example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract are all included. Any suitable solvent for extracting the extract from the cucumber may be used as long as it is a pharmaceutically acceptable organic solvent, and water or an organic solvent may be used, but is not limited thereto. For example, purified water, methanol ( Alcohols having 1 to 4 carbon atoms including methanol, ethanol, propanol, isopropanol, butanol, etc., acetone, ether, benzene, chloroform ( chloroform), ethyl acetate (ethyl acetate), methylene chloride (methylene chloride), hexane (hexane) and cyclohexane (cyclohexane) may be used alone or in combination, but most preferably ethanol.

As an extraction method, any one of methods such as hot water extraction, cold brew extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used, but most preferably hot water extraction. .

In addition, the desired extract may be additionally subjected to a conventional fractionation process or may be purified using a conventional purification method.

There is no limitation on the preparation method of the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention can be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying of the primary extract extracted by the above-described hot water extraction or solvent extraction method.

The term "composition" used in the present invention means a mixture in which other chemical components such as diluents or carriers are mixed with the cucumber extract of the present invention.

As used herein, the term “vehicle” is defined as a compound that facilitates the addition of a compound into a cell or tissue. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into cells or tissues of living organisms, but is not limited thereto.

As used herein, the term "diluent" is defined as a compound diluted in water that not only stabilizes the biologically active form of the subject compound, but also dissolves the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.

In the present invention, the term "prevention" refers to all activities to suppress or delay obesity by administration of the pharmaceutical composition according to the present invention.

As used herein, the term "treatment" refers to all activities that improve or beneficially change obesity symptoms by administration of the pharmaceutical composition. Those of ordinary skill in the art to which the present invention pertains will be able to determine the degree of improvement, enhancement and treatment by knowing the exact criteria of the disease for which the composition of the present application is effective by referring to the data presented by the Korean Medical Association, etc. will be.

Unless defined otherwise, all technical terms used in the present invention are used in the same meaning as commonly understood by one of ordinary skill in the art related to the present invention. In addition, although preferred methods or samples are described in this specification, those similar or equivalent thereto are also included in the scope of the present invention.

The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. As long as the adjuvant is known in the art, any one may be used without limitation, but, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase immunity.

The pharmaceutical composition according to the present invention may be prepared in the form of incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers usable in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories or sterile injection solutions according to conventional methods, respectively. .

When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, and gelatin in addition to active ingredients. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. can Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for suppositories, witepsol, tween 61, cacao paper, laurin paper, glycerogelatin, and the like may be used.

The pharmaceutical composition according to the present invention can be administered to a subject by various routes. All modes of administration are contemplated, eg oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The pharmaceutical composition may be formulated into various oral or parenteral dosage forms.

Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. chlorose, mannitol, sorbitol, cellulose and/or glycine), lubricants such as silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol. In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid or a disintegrant or effervescent mixture, such as its sodium salt, and/or absorbents, colorants, flavors, and sweeteners. The formulation may be prepared by conventional mixing, granulating or coating methods.

Representative formulations for parenteral administration are formulations for injection, and water, Ringer's solution, isotonic physiological saline or suspension may be used as a solvent for the formulation for injection. Sterile fixed oils of the above injectable preparations may be used as a solvent or suspension medium, and any bland fixed oil may be used for this purpose, including mono- and di-glycerides. The formulation for injection may use a fatty acid such as oleic acid.

Hereinafter, the present invention will be described in detail by embodiments of the present invention with reference to the accompanying drawings. However, the following examples are presented as examples of the present invention, and if it is determined that detailed descriptions of well-known techniques or configurations may unnecessarily obscure the gist of the present invention, the detailed descriptions may be omitted. , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the description of the claims described later and equivalent scopes interpreted therefrom.

In addition, the present invention provides a food composition for the prevention or improvement of obesity containing the extract as an active ingredient.

The type of food composition is not particularly limited as long as it is commonly manufactured and/or sold. For example, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes. It can be used in the form of pills, powders, granules, infusions, tablets, capsules or beverages, and includes all health functional foods in the conventional sense.

The health drink composition is not particularly limited in the liquid component except for containing the extract of the present invention, and may contain various flavoring agents or natural carbohydrates as additional components like conventional drinks.

Typically, the amount of the extract of the extract contained in the health functional food may be included in 0.1 to 50% by weight, preferably 1 to 40% by weight of the total weight of the food.

In addition, in the case of long-term intake for the purpose of health and hygiene or health control, it may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

Furthermore, the present invention includes the steps of extracting at 10 to 60 ° C. for 30 minutes to 48 hours by adding 50% ethanol to the pulverized cucumber fruit; And it provides a method for producing a composition for preventing or improving obesity, comprising the step of filtering and concentrating the extracted extract after the extraction and freeze-drying it.

Hereinafter, the present invention will be described in more detail through the following examples. However, the following examples are only examples for easily explaining the content and scope of the technical idea of the present invention, and thereby the technical scope of the present invention is not limited or changed. In addition, based on these examples, it can be easily determined by those skilled in the art that various modifications and changes are possible within the scope of the technical spirit of the present invention.

Example 1. Preparation of Ogapi Fruit Extract

1 kg of hot air-dried cucumber fruit was powdered, mixed with 3 L of 50% fermented alcohol, and stirred at room temperature for 24 hours. The above process was repeated twice with 3L of 50% fermented alcohol. After filtering on a filter paper and concentrating in a vacuum condition, an ethanol extract of the fruit of a cucumber plant was obtained.

Experimental Example 1. Confirmation of weight loss effect of cucumber fruit extract

In order to confirm the effect of reducing the weight of the extract of the fruit extract of cucumber, the experiment was conducted as follows.

The entire experimental group consisted of mice supplied with regular feed (Normal), high-fat diet (HFD) fed with high-fat diet, high-fat diet group with quince fruit extract administered, and high-fat diet group with guava leaves. They were classified into groups administered with the extract.

In order to observe the anti-obesity effect, 3 mg/mouse of guava leaf extract, a functional raw material for reducing body fat, was orally administered (p.o.) to the high-fat diet group at a concentration of 3 mg/mouse, which is a concentration of no toxicity, and guava leaf extract, which is a functional raw material for reducing body fat, as a control group.

As a result, as shown in FIG. 1, the weight increased by the high fat diet (HFD) was reduced in the experimental group administered with the cucumber fruit extract, especially in the case of the weight increased until the final day (4 weeks). It was confirmed that the extract administration group effectively suppressed weight gain, and it was found that the weight loss effect was more excellent when compared to the guava leaf extract administration group, which is a notified raw material.

Experimental Example 2. Confirmation of the effect of reducing the weight of the abdominal fat and epididymal fat of the extract of the fruit extract

In order to observe the anti-obesity effect, abdominal fat and epididymal fat of the entire experimental group of Experimental Example 1 were extracted to confirm weight changes using the fact that body fat weight increased with weight gain when obesity was induced by a high-fat diet.

As a result, as shown in FIG. 2, it was observed that the weight of the abdominal fat and epididymal fat increased by the high-fat diet were effectively reduced when the cucumber fruit extract was administered, and the fat weight reduction effect was more excellent when compared to the guava leaf extract-administered group. could find out

Experimental Example 3. Measurement of Toxic Expression Level of Organs of Acanthopanax Fruit Extract

Four tissues (liver, spleen, lung, and kidney) were removed and weight changes were measured to confirm organ toxicity caused by the administration of the extract of the cucumber fruit extract and the high-fat diet.

As a result, as shown in FIG. 3, it was confirmed that there was no significant change in the weight of the liver, spleen, lung, and kidney before and after administration of the extract of the fruit extract, and there was no significant effect on the weight reduction of organs by administration of the extract of the fruit extract. confirmed that

Although the preferred embodiments of the present invention have been described in detail above, the present invention is not limited to the specific embodiments described above, and is common in the art to which the present invention pertains without departing from the gist of the present invention claimed in the claims. Of course, various modifications and improvements are possible by those with knowledge of, and these modifications and improvements should not be individually understood from the technical spirit or prospect of the present invention.

Claims (7)

A pharmaceutical composition for the prevention or treatment of obesity, comprising an extract of a fruit extract of quinoa as an active ingredient. delete According to claim 1,
The solvent used for the extraction is extracted with any one solvent selected from the group consisting of methanol, ethanol, acetone, ethyl acetate, hexane, butanol, methylene chloride, water or a mixed solvent thereof, preventing or treating obesity pharmaceutical composition for use. According to claim 1,
The Ogapi extract is a pharmaceutical composition for preventing or treating obesity, characterized in that 50 to 80% ethanol extract is extracted at a temperature of 10 to 60 ° C. A health functional food composition for preventing or improving obesity, comprising an extract of quinoa fruit as an active ingredient. delete Adding 50% ethanol to the pulverized cucumber fruit and extracting at 10 to 60° C. for 30 minutes to 48 hours; and
Method for producing a composition for preventing or improving obesity, comprising the step of filtering and concentrating the extracted extract after the extraction and freeze-drying.

Images